Overview

A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)

Status:
Recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients with Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)
Phase:
Phase 2
Details
Lead Sponsor:
I-Mab Biopharma Co. Ltd.